Home > Adrenergic Receptor & Adrenergic Receptor  & > Salmeterol Xinafoate

Salmeterol Xinafoate

昔美酸沙美特罗,GR 33343X,GR33343X,GR-33343X

Salmeterol xinafoatexinafoate是长效β2肾上腺素受体激动剂，可作用于哮喘和慢性阻塞性肺病。

目录号
EY0606
EY0606
EY0606
EY0606
纯度
99.19%
99.19%
99.19%
99.19%
规格
5 mg
10 mg
25 mg
50 mg
原价
440
770
1500
2400
售价
440
770
1500
2400
库存
现货
现货
现货
现货
订购
订购
订购
订购
订购
订购
具体折扣请咨询客服

  • 生物活性

    Salmeterol Xinafoate is a long-acting β2-adrenergic receptor agonist with anti-inflammatory effects, used in the treatment of asthma symptoms and chronic obstructive pulmonary disease (COPD) symptoms.

  • 体外研究

  • 体内研究

  • 激酶实验

  • 细胞实验

  • 动物实验

  • 不同实验动物依据体表面积的等效剂量转换表（数据来源于FDA指南）

    动物 A (mg/kg) = 动物 B (mg/kg)×动物 B的Km系数/动物 A的Km系数


    例如，已知某工具药用于小鼠的剂量为88 mg/kg , 则用于大鼠的剂量换算方法：将88 mg/kg 乘以小鼠的Km系数（3），再除以大鼠的Km系数（6），得到该药物用于大鼠的等效剂量44 mg/kg。

  • 参考文献

    [1] Ullman, A., et al., 1990. Inhaled salmeterol and salbutamol in asthmatic patients. An evaluation of asthma symptoms and the possible development of tachyphylaxis. The American review of respiratory disease. 142(3): 571-5.
    [2] Twentyman, O P., et al., 1990. Protection against allergen-induced asthma by salmeterol. Lancet. 336(8727): 1338-42.

    分子式
    C36H45NO7    		 分子量
    603.75    		 CAS号
    94749-08-3    		 储存方式
    ﹣20 ℃冷藏长期储存。冰袋运输
    溶剂（常温）
    		 DMSO
    100 mg/mL    		 Water
    <1 mg/mL    		 Ethanol
    5 mg/mL

    体内溶解度

  • Clinical Trial Information ( data from http://clinicaltrials.gov )

    NCT Number Conditions Interventions Sponsor/Collaborators Phases Start Date Last Updated
    NCT00102882 Asthma Drug: fluticasone propionate/salmeterol|Drug: salmeterol xinafoate GlaxoSmithKline Phase 4 2004-10-01 2017-02-02
    NCT01395849 Respiratory Disorders Drug: Salmeterol and Fluticasone GlaxoSmithKline 2007-10-01 2011-07-14
    NCT01361984 Chronic Obstructive Pulmonary Disease|COPD|Emphysema|Chronic Bronchitis Drug: Nebulized arformoterol|Drug: Salmeterol University of California, Los Angeles|Sunovion Phase 4 2011-06-01 2012-07-18
    NCT02649478 Asthma Drug: Fluticasone / Salmeterol|Drug: Placebo|Drug: Advair Diskus 100/50 Roxane Laboratories|Vectura Limited 2014-08-01 2016-01-13
    NCT01636076 COPD Drug: QMF149|Drug: Salmeterol Novartis Pharmaceuticals|Novartis Phase 2 2012-11-01 2014-11-13
    NCT00595361 Asthma Drug: salmeterol Brigham and Women's Hospital 2008-01-01 2015-09-21
    NCT01271556 Salmeterol Effect Against an Acute Alveolar Fluid Clearance Challenge Secondary to Lung Fluid Overload in COPD Patients|Chronic Obstructive Pulmonary Disease|Bronchodilator Agents|Salmeterol Drug: Salmeterol|Procedure: saline infusion (0.9 per cent sodium chloride)|Other: Placebo University of Milan 2008-12-01 2011-01-05
    NCT01395862 Respiratory Disorders Drug: Salmeterol and Fluticasone GlaxoSmithKline 2007-11-01 2013-08-20
    NCT02558088 Pharmacokinetics in Healthy Young Men Drug: Salmeterol University of Copenhagen Phase 4 2014-09-01 2017-01-29
    NCT01431924 Asthma Drug: Higher-dose inhaled corticosteroids|Drug: Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination GlaxoSmithKline 2010-10-01 2013-02-21
    NCT00736801 Allergic Asthma Drug: Salmeterol and Salmeterol / Fluticasone University of Rostock|GlaxoSmithKline 2005-09-01 2008-08-20
    NCT01536587 Pulmonary Disease, Chronic Obstructive Drug: Salmeterol GlaxoSmithKline Phase 4 2012-07-01 2014-03-13
    NCT00452348 Asthma Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID GlaxoSmithKline Phase 4 2007-05-01 2016-10-27
    NCT01347060 Asthma Drug: fluticasone propionate/salmeterol xinafoate combination|Drug: inhaled corticosteroids GlaxoSmithKline 2009-07-01 2011-07-28
    NCT01332357 Asthma Drug: Fluticasone propionate/salmeterol combination ED MD|Drug: Fluticasone propionate/salmeterol combination OP MD GlaxoSmithKline 2009-06-01 2011-10-20
    NCT00914901 Asthma Drug: inhaled salmeterol Bispebjerg Hospital|Hormone Laboratory, Aker University Hospital, Oslo, Norway Phase 4 2009-07-01 2009-06-04
    NCT00525564 Chronic Obstructive Pulmonary Disease Drug: Placebo|Drug: Salmeterol diskus inhalation powder Laval University|GlaxoSmithKline Phase 4 2006-05-01 2007-09-05
    NCT01332409 Pulmonary Disease, Chronic Obstructive Drug: Salmeterol and Fluticasone GlaxoSmithKline 2009-08-01 2013-06-06
    NCT00448435 Bronchial Asthma Drug: GW815SF HFA MDI|Drug: salmeterol and fluticasone propionate GlaxoSmithKline Phase 3 2007-04-01 2010-06-03
    NCT01555138 Chronic Obstructive Pulmonary Disease Drug: Indacaterol|Drug: Salmeterol Novartis Pharmaceuticals|Novartis Phase 4 2012-02-01 2015-04-08
    NCT00830505 Asthma Drug: fluticasone/ salmeterol|Drug: fluticasone University of Dundee Phase 4 2009-02-01 2009-01-27
    NCT01337336 Pulmonary Disease, Chronic Obstructive Drug: fluticasone propionate/salmeterol xinafoate|Drug: Anticholinergics GlaxoSmithKline 2010-10-01 2011-06-16
    NCT01657487 Percentage of Annual Acute Exacerbation|Quality of Life Drug: Fluticasone/Salmeterol high dose Far Eastern Memorial Hospital|Research Ethics Review Committee Phase 4 2010-04-01 2012-08-03

    注：以上所有数据均来自公开文献，并不保证对所有实验均有效，数据仅供参考。

  • 相关化合物库

  • 使用AMQUAR产品发表文献后请联系我们

相关推荐

X
  • 联系人 ：
  • 收件地址 ：
  • 电话号码 ：
  • 单位名称 ：
  • 产品货号 ：
  • 产品规格 ：
  • 发票抬头以及单位税号 ：